CRIS Current Research Information System

GALIE', NAZZARENO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.563
AS - Asia 17.755
EU - Europa 12.273
SA - Sud America 1.336
AF - Africa 945
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 17
Totale 50.916
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.272
SG - Singapore 4.760
VN - Vietnam 4.649
CN - Cina 4.347
GB - Regno Unito 2.886
IT - Italia 2.555
DE - Germania 1.600
HK - Hong Kong 1.296
BR - Brasile 960
FR - Francia 915
SE - Svezia 811
IN - India 798
UA - Ucraina 705
RU - Federazione Russa 703
IE - Irlanda 498
NL - Olanda 415
KR - Corea 335
JP - Giappone 313
BD - Bangladesh 290
FI - Finlandia 286
ZA - Sudafrica 283
CI - Costa d'Avorio 254
EE - Estonia 200
AR - Argentina 155
CA - Canada 154
CH - Svizzera 149
TG - Togo 134
JO - Giordania 131
PH - Filippine 111
ID - Indonesia 107
AT - Austria 102
BG - Bulgaria 92
TH - Thailandia 92
SC - Seychelles 89
TR - Turchia 89
IQ - Iraq 86
MX - Messico 71
PK - Pakistan 65
PL - Polonia 62
EC - Ecuador 58
CO - Colombia 51
TW - Taiwan 50
ES - Italia 47
BE - Belgio 44
SA - Arabia Saudita 41
NG - Nigeria 39
CL - Cile 34
GR - Grecia 32
EG - Egitto 30
UZ - Uzbekistan 30
IR - Iran 28
AU - Australia 23
HU - Ungheria 22
LT - Lituania 22
PY - Paraguay 22
VE - Venezuela 22
MY - Malesia 20
JM - Giamaica 19
RO - Romania 19
PE - Perù 18
HR - Croazia 17
MA - Marocco 17
KE - Kenya 16
DZ - Algeria 15
LB - Libano 15
CZ - Repubblica Ceca 14
AL - Albania 13
AZ - Azerbaigian 13
NE - Niger 13
UY - Uruguay 13
AE - Emirati Arabi Uniti 12
KZ - Kazakistan 12
ET - Etiopia 11
DK - Danimarca 10
DO - Repubblica Dominicana 10
OM - Oman 10
PS - Palestinian Territory 9
TN - Tunisia 9
XK - ???statistics.table.value.countryCode.XK??? 9
CR - Costa Rica 8
HN - Honduras 8
SK - Slovacchia (Repubblica Slovacca) 8
SY - Repubblica araba siriana 8
IL - Israele 7
PT - Portogallo 7
RS - Serbia 7
NI - Nicaragua 6
SN - Senegal 6
GH - Ghana 5
GT - Guatemala 5
NP - Nepal 5
A2 - ???statistics.table.value.countryCode.A2??? 4
EU - Europa 4
GE - Georgia 4
LU - Lussemburgo 4
LV - Lettonia 4
MK - Macedonia 4
NZ - Nuova Zelanda 4
BO - Bolivia 3
BY - Bielorussia 3
Totale 50.843
Salva come PNG Salva come JPEG
Città #
Singapore 3.276
Southend 2.446
Ashburn 1.915
Fairfield 1.759
Hong Kong 1.247
Ho Chi Minh City 1.079
Chandler 1.061
San Jose 1.050
Hanoi 940
Woodbridge 882
Wilmington 807
Seattle 745
Houston 742
Hefei 715
Dong Ket 674
Santa Clara 672
Beijing 668
Princeton 650
Cambridge 594
Dublin 493
Boardman 467
Jacksonville 440
Ann Arbor 421
Lauterbourg 393
Bologna 362
Council Bluffs 313
Los Angeles 287
Seoul 279
Tokyo 274
Westminster 261
Abidjan 254
New York 252
Padova 249
Nanjing 242
Milan 227
Berlin 192
Buffalo 185
Helsinki 171
São Paulo 152
Jinan 149
Turin 146
Haiphong 144
The Dalles 142
Da Nang 135
Lomé 133
Saint Petersburg 127
Amman 126
Dallas 125
Shenyang 125
San Diego 123
Redondo Beach 120
Frankfurt am Main 112
Bern 110
Rome 107
Guangzhou 101
Mülheim 95
Changsha 91
Sofia 89
Hebei 84
Bengaluru 82
Shanghai 81
Medford 80
Munich 78
Tianjin 74
Nuremberg 72
Des Moines 68
London 68
Chicago 66
Nanchang 66
Phoenix 65
Lappeenranta 62
Hangzhou 61
Jiaxing 58
Zhengzhou 58
Vienna 56
Johannesburg 54
Turku 52
Mahé 48
Redmond 48
Biên Hòa 47
Jakarta 47
Can Tho 46
Florence 46
Toronto 46
Warsaw 46
Yubileyny 45
Dearborn 44
Enfield 44
Shenzhen 44
Olalla 43
Bangkok 42
Brussels 42
Hải Dương 42
Amsterdam 41
Falls Church 41
Bremen 40
Thái Nguyên 39
Falkenstein 38
Baghdad 36
Abeokuta 35
Totale 32.411
Salva come PNG Salva come JPEG
Nome #
Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA 439
Prolasso valvolare mitralico e disgiunzione mitro-anulare. La consapevolezza di un possibile substrato aritmico 360
Female gender and mortality in ST-segment-elevation myocardial infarction treated with primary PCI 280
[Pulmonary hypertension in chronic lung diseases] 279
Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells 271
Sex-Related Disparities in Cardiac Masses: Clinical Features and Outcomes 267
L’angioplastica delle arterie polmonari nel cuore polmonare cronico tromboembolico: 5 anni di esperienza in Italia 266
Is Pulmonary Artery Pulsatility Index (PAPi) a Predictor of Outcome after Pulmonary Endarterectomy? 262
A new CT-score as index of hemodynamic changes in patients with chronic thromboembolic pulmonary hypertension 260
Complicanze del cateterismo cardiaco destro in pazienti con ipertensione polmonare precapillare di grado severo. 257
Lung neovascularity in pulmonary arterial hypertension associated with congenital heart defects and idiopathic pulmonary arterial hypertension: study of 198 patients 250
A Combined Targeted and Whole Exome Sequencing Approach Identified Novel Candidate Genes Involved in Heritable Pulmonary Arterial Hypertension 247
2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. 243
Diagnostic Accuracy of Cardiac Computed Tomography and 18F-Fluorodeoxyglucose With Positron Emission Tomography in Cardiac Masses 242
Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: Real-world insights 239
Angioplastica delle arterie polmonari nel cuore polmonare cronico tromboembolico: un caso clinico paradigmatico 235
Il test acuto di vasoreattività nei pazienti con ipertensione arteriosa polmonare. 234
Evaluation of mosaic pattern areas in HRCT with Min-IP reconstructions in patients with pulmonary hypertension: could this evaluation replace lung perfusion scintigraphy? 230
Pulmonary Arterial Hypertension associated to connective tissue diseases 226
Effetti emodinamici e funzionali dell'epoprostenolo in associazione agli antagonisti recettoriali dell'endotelina e agli inibitori delle fosfodiesterasi-5 225
Application of a new pulmonary artery obstruction score in the prognostic evaluation of acute pulmonary embolism: comparison with clinical and haemodynamic parameters [Applicazione di un nuovo score di ostruzione vascolare nella valutazione prognostica dell'embolia polmonare acuta. Confronto con i parametri clinico-emodinamici] 219
Electrocardiogram analysis in Anderson-Fabry disease: a valuable tool for progressive phenotypic expression tracking 217
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 217
Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes 214
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension 213
Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people 205
Regressione delle alterazioni elettrocardiografiche indicative di ipertrofia ventricolare destra nei pazienti con ipertensione arteriosa polmonare. 203
Aiming at the appropriate target for the treatment of pulmonary hypertension due to left heart disease 203
In vitro thrombogenicity of drug-eluting and bare metal stents 202
Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study 202
Use of Diltiazem in Chronic Rate Control for Atrial Fibrillation: A Prospective Case-Control Study 197
Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. 195
BMPR2 mutations and survival in pulmonary arterial hypertension: An individual participant data meta-analysis 195
Dissecting histone deacetylase role in pulmonary arterial smooth muscle cell proliferation and migration 194
Andamento clinico, emodinamico e dei livelli plasmatici dell’NT-pro BNP in pazienti con ipertensione polmonare precapillare 191
Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. 191
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension 190
Development and Validation of a Diagnostic Echocardiographic Mass Score in the Approach to Cardiac Masses 188
Secondary prevention medical therapy and outcomes in patients with myocardial infarction with non-obstructive coronary artery disease 188
Therapeutic alternatives in chronic thromboembolic pulmonary hypertension: from pulmonary endarterectomy to balloon pulmonary angioplasty to medical therapy. State of the art from a multidisciplinary team 188
Correlations Between Cardiac Magnetic Resonance and Myocardial Histologic Findings in Fabry Disease 187
Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson–Fabry disease 187
Occurring of In Vitro Functional Vasculogenic Pericytes from Human Circulating Early Endothelial Precursor Cell Culture 186
Densitometric CT evaluation of acute and chronic thromboembolic filling defects of the pulmonary arteries before and after contrast injection = Valutazione densitometrica dei difetti di riempimento tromboembolici acuti e cronici delle arterie polmonari prima e dopo somministrazione di mezzo di contrasto 186
Ambrisentan therapy for pulmonary arterial hypertension. 185
[Pulmonary hypertension due to left heart diseases] 185
A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines 185
Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition. 182
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension 182
Effetti del trattamento con sildenafil nei pazienti con ipertensione arteriosa polmonare idiopatica, associata e cuore polmonare cronico tromboembolico. 181
Anticoagulant treatment in patients with pulmonary arterial hypertension associated with systemic sclerosis: More shadows than lights 179
Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension. 177
Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA 176
Preoperative checklist to reduce the risk of cardiac implantable electronic device infections 176
Significato prognostico dell'aerea del rigurgito tricuspidalico nei pazienti con ipertensione arteriosa polmonare idiopatica trattati secondo le attuali linee guida. 175
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. 174
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. 174
Current therapeutic approaches to pulmonary arterial hypertension. 174
Genetics and clinical phenotype of Erdheim–Chester disease: A case report of constrictive pericarditis and a systematic review of the literature 173
New insights on pulmonary arterial hypertension. 173
The endothelin system in pulmonary arterial hypertension. 173
Effetti clinici ed emodinamici del trattamento con sildenafil nei pazienti con ipertensione arteriosa polmonare. 173
Genere femminile e ipertensione arteriosa polmonare: una relazione complessa Female gender and pulmonary arterial hypertension: a complex relationship 173
Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. 172
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS 172
Pulmonary endarterectomy: is there an alternative to profound hypothermia with cardiocirculatory arrest? 171
Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study 170
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. 170
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. 168
Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. 167
Sildenafil therapy in patients with porto-pulmonary hypertension 167
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism 167
Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension 167
Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina 167
Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients 167
Clinical presentations leading to arrhythmogenic left ventricular cardiomyopathy 166
Pulmonary Arterial Hypertension Associated with Portal Hypertension and HIV Infection: Comparative Characteristics and Prognostic Predictors 165
Clinical classification of pulmonary hypertension. 164
Pulmonary endarterectomy: an alternative to circulatory arrest and deep hypothermia: mid-term results 164
Confronto tra antagonista recettoriali selettivi e non selettivi dell'endotelina nel trattamento dell'ipertensione arteriosa polmonare. 162
Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study 162
Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients 162
Primary malignant pericardial tumour in Lynch syndrome 161
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. 160
Predicting and improving outcomes of transcatheter aortic valve replacement in older adults and the elderly 160
Cardiologia pediatrica. Problematiche cliniche 160
Pulmonary hypertension in primary Sjogren's syndrome: report of a case and review of the literature. 159
Coronary Protection to Prevent Coronary Obstruction During Transcatheter Aortic Valve Replacement: A Multicenter International Registry 159
Impact of Elective, Uncomplicated Target Lesion Revascularization on Cardiac Mortality After Elective Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery Disease 159
Pulmonary arterial hypertension. Part II: Medical and surgical treatment 158
Effetti del sildenafil in soggetti con cuore polmonare cronico tromboembolico 158
The role of physical activity in individuals with cardiovascular risk factors: An opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport 158
Prognostic value of high-sensitivity cardiac troponin I early after coronary artery bypass graft surgery 157
Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. 156
Rare causes of pulmonary hypertension. Spectrum of radiological findings and review of the literature 156
2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension 155
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study 154
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS) 154
Patisiran for the treatment of patients with p.Ile88Leu hereditary transthyretin amyloidosis: an Italian real-life experience 152
Pulmonary arterial hypertension: a look to the future. 152
Totale 19.438
Salva come PNG Salva come JPEG
Categoria #
all - tutte 152.679
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 152.679
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.026 0 0 0 0 0 0 0 0 0 0 0 1.026
2021/20225.019 479 181 333 320 432 272 125 419 186 267 1.085 920
2022/20235.534 549 694 264 661 294 398 205 275 1.007 236 564 387
2023/20241.796 135 258 107 148 163 264 103 134 79 190 95 120
2024/20257.531 323 1.265 797 505 1.038 469 493 248 173 475 382 1.363
2025/202618.777 1.492 1.750 1.733 1.453 2.091 1.004 1.943 689 3.770 1.331 821 700
Totale 51.858